BCMA-Specific Antibodies for Selective B-Cell Targeting

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for B-cell-related diseases lack specific targeting agents that can effectively differentiate between various B-cell subsets, such as plasma cells, memory B-cells, and naïve B-cells, limiting therapeutic options for conditions like multiple myeloma and Hodgkin's Lymphoma.

Innovation Solution

Development of antibodies that specifically bind to the B-cell Maturation Antigen (BCMA), allowing for targeted therapy of B-cell subsets by recognizing and binding to BCMA on the surface of these cells, potentially leading to the depletion of neoplastic B-cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If current treatments for B-cell-related diseases are used, then general B-cell targeting is achieved, but specific differentiation between various B-cell subsets (plasma cells, memory B-cells, naïve B-cells) is lost

Engineering Contradiction:

Improvespecificity of B-cell subset targetingVSAvoidtherapeutic options for different B-cell conditions

Core Design Contradiction:

Measurement precisionVSAdaptability or versatility

Solution Approach 1:

The patent segments the broad B-cell population into distinct subsets by developing antibodies that specifically recognize unique markers on each subset (e.g., BCMA for plasma cells, CD20 for naïve B-cells). This allows selective targeting of specific B-cell populations while preserving the ability to address different B-cell related conditions through appropriate antibody selection or combination.

Inventive Principle:

Principle #1Segmentation

2Reliability

If antibodies targeting BCMA are used, then specific binding to BCMA-expressing B-cells is achieved, but potential off-target effects on normal cells may occur

Engineering Contradiction:

Improvespecific binding to target cellsVSAvoidimpact on normal cells

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by designing antibodies with highly specific epitope recognition on BCMA, ensuring that the therapeutic effect is localized to BCMA-expressing malignant cells while sparing normal cells that either do not express BCMA or express it at significantly lower levels. The antibodies are engineered to bind with high affinity and specificity to particular conformational epitopes on BCMA.

Inventive Principle:

Principle #3Local quality

Data Source

PatentUS12116415B2Anti-BCMA antibodies

Publication Date: 2024.10.15 SINGLE CELL TECHNOLOGY INC

AI summary

Provided are antibodies that recognize the B-Cell Maturation Antigen (BCMA) and methods of use thereof.